Anifrolumab

Unassigned

New Medicines

Systemic lupus erythematosus (SLE)

Information

New molecular entity
AstraZeneca
MedImmune

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

First-in-class fully human monoclonal antibody that binds to subunit 1 of the Type I IFN receptor, inhibiting the activity of all Type I IFNs including IFN-α, IFN-β and IFN-ω.
The UK prevalence of SLE is 25-28 per 100,000 population; over 90% develop arthralgia and myalgia.
Systemic lupus erythematosus (SLE)
Intravenous